T1	PROC 44 75	Estudio de eficacia y seguridad
T2	CHEM 93 103	Durvalumab
#1	AnnotatorNotes T2	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	PROC 125 164	Estudio abierto, multicéntrico y global
T4	PROC 170 204	evaluar la eficacia y la seguridad
#2	AnnotatorNotes T4	C0511730; Identify product efficacy and safety issues; Health Care Activity
T5	CHEM 284 294	durvalumab
#3	AnnotatorNotes T5	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T6	PROC 304 314	protocolos
#4	AnnotatorNotes T6	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T7	DISO 360 366	cáncer
#5	AnnotatorNotes T7	C0006826; Malignant Neoplasms; Neoplastic Process
T8	PROC 1421 1434	retratamiento
#6	AnnotatorNotes T8	C0376495; Retreatments; Therapeutic or Preventive Procedure
T9	PROC 1539 1552	retratamiento
#7	AnnotatorNotes T9	C0376495; Retreatments; Therapeutic or Preventive Procedure
T10	CHEM 680 690	durvalumab
#8	AnnotatorNotes T10	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	PROC 694 705	monoterapia
#9	AnnotatorNotes T11	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T12	CHEM 740 750	durvalumab
#10	AnnotatorNotes T12	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	PROC 757 772	estudio clínico
#11	AnnotatorNotes T13	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T14	CHEM 909 919	durvalumab
#12	AnnotatorNotes T14	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T15	PROC 944 970	tratamiento antineoplásico
#13	AnnotatorNotes T15	C0920425; cancer treatment; Therapeutic or Preventive Procedure
T16	PROC 1056 1084	tratamientos antineoplásicos
T17	PROC 1099 1104	pauta
#14	AnnotatorNotes T17	C0935576; treatment guideline; Therapeutic or Preventive Procedure
T18	CHEM 1108 1118	durvalumab
#15	AnnotatorNotes T18	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T19	PROC 1189 1225	consentimiento informado por escrito
#16	AnnotatorNotes T19	C0811741; Obtain informed written consent; Health Care Activity
T20	PROC 1407 1418	tratamiento
#17	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	PROC 1482 1493	tratamiento
#18	AnnotatorNotes T21	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T22	PROC 1502 1517	estudio clínico
#19	AnnotatorNotes T22	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T23	PROC 1573 1584	tratamiento
#20	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	PROC 1607 1618	seguimiento
#21	AnnotatorNotes T24	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T25	CHEM 1644 1654	durvalumab
#22	AnnotatorNotes T25	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T26	PROC 1668 1709	tratamiento concomitante de quimioterapia
#23	AnnotatorNotes T26	C5203979; Concurrent Chemotherapy; Therapeutic or Preventive Procedure
T27	PROC 1272 1286	procedimientos
#24	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T28	CHEM 1756 1764	hormonal
#25	AnnotatorNotes T28	C0019932; Hormones; Hormone
T29	PROC 1773 1795	tratamiento del cáncer
#26	AnnotatorNotes T29	C0920425; cancer treatment; Therapeutic or Preventive Procedure
T30	DISO 1831 1869	toxicidad inmunitaria o no inmunitaria
T31	CHEM 1912 1922	durvalumab
#27	AnnotatorNotes T31	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T32	PROC 1929 1944	estudio clínico
#28	AnnotatorNotes T32	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T33	PROC 1959 1970	Diagnóstico
#29	AnnotatorNotes T33	C0011900; Diagnosis; Diagnostic Procedure
T34	DISO 1980 1998	neoplasia primaria
T35	PROC 2026 2041	estudio clínico
#30	AnnotatorNotes T35	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T36	CHEM 956 970	antineoplásico
#31	AnnotatorNotes T36	C0003392; Antineoplastic Agents; Organic Chemical · Pharmacologic Substance
T37	CHEM 1069 1084	antineoplásicos
#32	AnnotatorNotes T37	C0003392; Antineoplastic Agents; Organic Chemical · Pharmacologic Substance
T38	CHEM 1626 1632	agente
#33	AnnotatorNotes T38	C0450442; Agent; Chemical Viewed Functionally
T39	DISO 1789 1795	cáncer
#34	AnnotatorNotes T39	C0006826; Malignant Neoplasms; Neoplastic Process
T40	Date 12 16	2019
T41	Date 76 89	a largo plazo
T42	Date 205 218	a largo plazo
T43	LIVB 222 231	pacientes
#35	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	LIVB 428 437	pacientes
#36	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T45	Age 450 471	18 años de edad o más
T46	LIVB 513 520	sujetos
#37	AnnotatorNotes T46	C0681850; Study Subject; Group
T47	Age 521 539	menores de 20 años
T48	LIVB 609 615	sujeto
#38	AnnotatorNotes T48	C0681850; Study Subject; Group
T49	LIVB 621 640	representante legal
#39	AnnotatorNotes T49	C4288823; Legal Representative for the Study; Human
T50	LIVB 649 658	pacientes
#40	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	LIVB 880 889	pacientes
#41	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T52	LIVB 1128 1137	pacientes
#42	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	LIVB 1385 1394	pacientes
#43	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	LIVB 1439 1448	Pacientes
#44	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T55	Date 1467 1478	actualmente
T56	LIVB 1525 1534	pacientes
#45	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	Neg_cue 1637 1639	no
T58	LIVB 1799 1808	Pacientes
#46	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T59	PROC 1895 1907	interrupción
#47	AnnotatorNotes T59	C0850893; stop medication; Therapeutic or Preventive Procedure
T60	PROC 1031 1043	interrumpido
#48	AnnotatorNotes T60	C0850893; stop medication; Therapeutic or Preventive Procedure
T61	CHEM 1711 1736	producto en investigación
#49	AnnotatorNotes T61	C0013230; Investigational New Drugs; Pharmacologic Substance
T62	CHEM 1738 1741	PEI
#50	AnnotatorNotes T62	C0013230; Investigational New Drugs; Pharmacologic Substance
T63	PROC 1244 1251	visitas
#51	AnnotatorNotes T63	C1512346; Patient Visit; Health Care Activity
A1	Assertion T25 Negated
A2	Status T10 History_of
A3	Status T11 History_of
A4	Status T12 History_of
A6	Status T14 History_of
A7	Status T15 History_of
A8	Status T36 History_of
A9	Status T16 History_of
A10	Status T37 History_of
A11	Status T17 History_of
A12	Status T18 History_of
A13	Status T30 History_of
A14	Status T59 History_of
A15	Status T31 History_of
A16	Status T23 History_of
A17	Status T38 History_of
A18	Status T25 History_of
A19	Status T5 History_of
#52	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#53	AnnotatorNotes T41	C0443252; Long-term; Temporal Concept
#54	AnnotatorNotes T42	C0443252; Long-term; Temporal Concept
#55	AnnotatorNotes T16	C0920425; cancer treatment; Therapeutic or Preventive Procedure
#56	AnnotatorNotes T55	C0521116; Current (present time); Temporal Concept 
T64	Quantifier_or_Qualifier 1841 1852	inmunitaria
#57	AnnotatorNotes T64	C4330477; Immune-mediated; Qualitative Concept
T65	Quantifier_or_Qualifier 1858 1869	inmunitaria
A5	Assertion T65 Negated
#58	AnnotatorNotes T65	C4330477; Immune-mediated; Qualitative Concept
T66	Neg_cue 1855 1857	no
R1	Overlap Arg1:T1 Arg2:T41	
R2	Overlap Arg1:T4 Arg2:T42	
R3	Experiences Arg1:T43 Arg2:T5	
R4	Has_Age Arg1:T44 Arg2:T45	
R5	Has_Age Arg1:T46 Arg2:T47	
R6	Experiences Arg1:T50 Arg2:T10	
R7	Used_for Arg1:T10 Arg2:T11	
R8	Experiences Arg1:T50 Arg2:T12	
R9	Experiences Arg1:T51 Arg2:T14	
R10	Combined_with Arg1:T14 Arg2:T15	
R11	Used_for Arg1:T36 Arg2:T15	
T67	Quantifier_or_Qualifier 971 981	autorizado
#59	AnnotatorNotes T67	C1555472; Authorized; Finding
R12	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T67	
A20	Status T67 History_of
R13	Experiences Arg1:T51 Arg2:T60	
R14	Experiences Arg1:T51 Arg2:T16	
R15	Used_for Arg1:T37 Arg2:T16	
T68	Observation 1018 1028;1044 1084	finalizado el resto de tratamientos antineoplásicos
#60	AnnotatorNotes T68	C0580352; Treatment completed; Finding (?)
R16	Used_for Arg1:T18 Arg2:T17	
R17	Experiences Arg1:T51 Arg2:T17	
T69	Observation 1150 1160	dispuestos
#61	AnnotatorNotes T69	C0600109; Willing; Finding
R18	Has_Quantifier_or_Qualifier Arg1:T52 Arg2:T69	
T70	Observation 1167 1286	capaces de otorgar el consentimiento informado por escrito y cumplir con las visitas programadas y otros procedimientos
R19	Has_Quantifier_or_Qualifier Arg1:T52 Arg2:T70	
R20	Overlap Arg1:T69 Arg2:T19	
R21	Overlap Arg1:T70 Arg2:T19	
R22	Overlap Arg1:T69 Arg2:T63	
R23	Overlap Arg1:T69 Arg2:T27	
R24	Experiences Arg1:T53 Arg2:T20	
R25	Experiences Arg1:T53 Arg2:T8	
R26	Overlap Arg1:T21 Arg2:T55	
R27	Experiences Arg1:T54 Arg2:T21	
R28	Experiences Arg1:T56 Arg2:T9	
R29	Experiences Arg1:T56 Arg2:T23	
R30	Overlap Arg1:T23 Arg2:T24	
R31	Used_for Arg1:T38 Arg2:T23	
R32	Negation Arg1:T57 Arg2:T25	
R33	Used_for Arg1:T25 Arg2:T23	
T71	Quantifier_or_Qualifier 1744 1753	biológico
#62	AnnotatorNotes T71	C0205460; biological; Qualitative Concept
R34	Has_Quantifier_or_Qualifier Arg1:T62 Arg2:T71	
R35	Has_Quantifier_or_Qualifier Arg1:T61 Arg2:T71	
R36	Used_for Arg1:T26 Arg2:T29	
R37	Used_for Arg1:T61 Arg2:T29	
R38	Used_for Arg1:T62 Arg2:T29	
R39	Used_for Arg1:T28 Arg2:T29	
R40	Negation Arg1:T66 Arg2:T65	
R41	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T64	
R42	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T65	
R43	Experiences Arg1:T58 Arg2:T30	
R44	Experiences Arg1:T58 Arg2:T59	
R45	Used_for Arg1:T31 Arg2:T59	
R46	Before Arg1:T30 Arg2:T59	
R47	Before Arg1:T31 Arg2:T30	
T72	Quantifier_or_Qualifier 1974 1979	nueva
#63	AnnotatorNotes T72	C0205314; New; Qualitative Concept
R48	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T72	
#64	AnnotatorNotes T34	C0677930; Primary Neoplasm; Neoplastic Process
T73	PROC 2008 2019	inscripción
R49	Before Arg1:T73 Arg2:T33	
R50	Before Arg1:T73 Arg2:T34	
#65	AnnotatorNotes T73	C4041024; Enrollment in clinical trial; Research Activity
R51	Before Arg1:T73 Arg2:T35	
T74	PROC 844 855	inscripción
#66	AnnotatorNotes T74	C4041024; Enrollment in clinical trial; Research Activity
T75	CONC 823 835	autorización
R52	Before Arg1:T75 Arg2:T74	
R53	Used_for Arg1:T37 Arg2:T60	
R54	Used_for Arg1:T14 Arg2:T60	
R55	Used_for Arg1:T18 Arg2:T60	
T76	Observation 1453 1466;1494 1517	se encuentren en otro estudio clínico
A21	Experiencer T58 Patient
A22	Experiencer T43 Patient
A23	Experiencer T44 Patient
A24	Experiencer T46 Patient
A25	Experiencer T48 Patient
A26	Experiencer T49 Other
A27	Experiencer T50 Patient
A28	Experiencer T51 Patient
A29	Experiencer T52 Patient
A30	Experiencer T53 Patient
A31	Experiencer T56 Patient
A32	Experiencer T54 Patient
